A detailed history of Hexagon Capital Partners LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Hexagon Capital Partners LLC holds 5,890 shares of NVO stock, worth $522,501. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,890
Previous 5,945 0.93%
Holding current value
$522,501
Previous $848,000 17.33%
% of portfolio
0.14%
Previous 0.19%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$119.07 - $145.42 $6,548 - $7,998
-55 Reduced 0.93%
5,890 $701,000
Q2 2024

Jul 12, 2024

BUY
$122.71 - $146.91 $13,498 - $16,160
110 Added 1.89%
5,945 $848,000
Q1 2024

Apr 18, 2024

BUY
$102.11 - $135.92 $23,485 - $31,261
230 Added 4.1%
5,835 $749,000
Q4 2023

Feb 05, 2024

BUY
$87.78 - $105.45 $92,959 - $111,671
1,059 Added 23.3%
5,605 $579,000
Q3 2023

Oct 23, 2023

BUY
$90.94 - $199.54 $213,890 - $469,318
2,352 Added 107.2%
4,546 $413,000
Q2 2023

Jul 24, 2023

SELL
$155.98 - $172.65 $2,495 - $2,762
-16 Reduced 0.72%
2,194 $355,000
Q1 2023

Apr 24, 2023

BUY
$132.34 - $159.14 $3,573 - $4,296
27 Added 1.24%
2,210 $351,000
Q4 2022

Jan 13, 2023

SELL
$102.55 - $135.33 $8,101 - $10,691
-79 Reduced 3.49%
2,183 $0
Q3 2022

Oct 17, 2022

BUY
$95.28 - $116.93 $33,252 - $40,808
349 Added 18.24%
2,262 $225,000
Q2 2022

Jul 21, 2022

BUY
$103.24 - $121.81 $30,146 - $35,568
292 Added 18.01%
1,913 $213,000
Q1 2022

Apr 13, 2022

BUY
$93.1 - $112.54 $1,489 - $1,800
16 Added 1.0%
1,621 $180,000
Q3 2021

Nov 12, 2021

BUY
$84.42 - $106.62 $2,448 - $3,091
29 Added 1.84%
1,605 $154,000
Q1 2021

May 13, 2021

BUY
$67.06 - $75.82 $2,816 - $3,184
42 Added 2.74%
1,576 $106,000
Q4 2020

Feb 05, 2021

SELL
$63.89 - $73.8 $1,277 - $1,476
-20 Reduced 1.29%
1,534 $107,000
Q3 2020

Nov 10, 2020

BUY
$63.69 - $70.22 $98,974 - $109,121
1,554 New
1,554 $101,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $200B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Hexagon Capital Partners LLC Portfolio

Follow Hexagon Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hexagon Capital Partners LLC with notifications on news.